NSE: AJANTPHARM | BSE: 532331

Expensive Performer

Download real time

2481.00 -140.15 (-5.35%)

28.81% Fall from 52W High

73,470 NSE+BSE Volume

NSE 04 Apr, 2025 1:18 PM (IST)

30,990.7

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

07 Nov 2019

2481.00

-5.35%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

06 Nov 2019

2481.00

-5.35%

Ajanta Pharma - 2QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

06 Aug 2019

2481.00

-5.35%

Ajanta Pharma Ltd. - Result Update - 06 August 2019

Results Update: Ajanta Pharma Ltd.

Way2Wealth

Ajanta reported growth across most of the financial line items YoY and QoQ. Revenue/EBITDA/PAT grew by 20%/7%/9%YoY, while sequentially it grew by 19%/32%/30%. However, gross and EBITDA margins declined 700bps and 335bps YoY....

Ajanta Pharma Ltd. has lost -25.96% in the last 6 Months

Ajanta Pharma Ltd.

01 Aug 2019

2481.00

-5.35%

Ajanta Pharma - 1QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

01 Aug 2019

2481.00

-5.35%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

02 May 2019

2481.00

-5.35%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in the dermatology segment due to increased competition in existing products and slow offtake in new launches may impact near term...

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

01 May 2019

2481.00

-5.35%

Africa/institutional anti-malaria drag performance???

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

1 May 2019 Revenue declined 3% YoY to INR5.1b (in-line) in 4QFY19, largely on account of the weakness in (a) institutional anti-malaria (-26% YoY; 9% of sales) and (b) Africa branded generic (-31% YoY; 15% of sales) businesses. However, the impact was partly mitigated by the ramp-up in US sales (+79% YoY; 15% of sales) and steady growth in the India business (+8% YoY; 30% of sales)/Asia (+9% YoY; 28% of sales). EBITDA margin, too, contracted 164bp YoY to 24.7% (our v/s 19.8% in the year-ago period) and RM cost. Other expenses, however, declined to 34% of sales (36.2% in 4QFY18), providing some comfort to the FY19, sales/EBITDA/PAT declined 4%/14%/17% YoY to INR20.5b/INR5.6b/INR3.8b. In FY19, AJP filed 13 and received 12 ANDA approvals (including two tentative approvals). The company has commercialized 25 ANDAs till date.

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

01 Feb 2019

2481.00

-5.35%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma's Q3FY19 results were below I-direct estimates on all fronts mainly due to lower-than-exacted export formulation sales Revenues declined 17.4% YoY to | 485.1 crore (I-direct estimate: | 522.6 crore) due to 26.7% YoY decline in export formulations to...

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

03 Nov 2018, 12:19PM

2481.00

-5.35%

Ajanta Pharma Ltd Q2FY19 results Comment

Results Update: Ajanta Pharma Ltd.

HDFC Securities

Ajanta Pharma Ltd Q2FY19 results Comment Revenue increased by 6.48% to Rs. 544.11 Cr in Q2FY19 when compared to the previous quarter. Also, it rose by 0.69% when compared with Q2FY18

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

01 Nov 2018

2481.00

-5.35%

Ajanta Pharma-Result Update

Buy: Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma (AJP) has delivered a better-than-expected performance on all operational metrics in 2QFY19 led by strong sales growth in Asia/US as well as lower-than-expected decline in Africa sales. Domestic business reported flat growth due to high YoY base led by channel re-filling post GST roll-out. Despite marginal sales growth, AJP's EBITDA de-grew by 9.5% YoY to Rs1.7bn on account of higher staff and other operating expenditure, owing to which EBITDA margin contracted by 345bps YoY to 30.5%. However, AJP's gross margin expanded by 255bps YoY to 82.4% due to better product-mix. Led by higher taxes, PAT de-grew by 4.9% YoY to Rs1.3bn. The Company is expected to file 10-12 ANDAs with the USFDA in FY19E. LPC maintained...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

No results found

Is Ajanta Pharma Ltd. worth buying?

186 Votes:

Buy 76.88%

Sell 16.13%

Hold 6.99%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf